BacterioScan, Inc. is a medical device company dedicated to changing the way infectious disease is diagnosed and treated. We are driven by a fundamental desire to ensure the successful use of antibiotics.
Our innovative instrumentation platform is built on the fast detection and antibiotic susceptibility testing of infectious pathogens. We produce reliable, precision instrumentation that quickly detects and measures microorganism growth in liquid specimens, determines if it is resistant to a range of antibiotics and provides clinicians with patient-specific guidance on the fastest and most cost-effective antibiotic treatment.
Our technologies help to improve the quality of antibiotic therapy, reduce excess or inappropriate use of antibiotics and deter antibiotic resistance. The real-time bacteria detection and antimicrobial resistance data we collect and aggregate through our network can be used to inform clinical decision-making and the medical community’s response to emerging threats related to infectious disease and antibiotic resistance worldwide.
Our innovative instrumentation platform is built on the fast detection and antibiotic susceptibility testing of infectious pathogens. We produce reliable, precision instrumentation that quickly detects and measures microorganism growth in liquid specimens, determines if it is resistant to a range of antibiotics and provides clinicians with patient-specific guidance on the fastest and most cost-effective antibiotic treatment.
Our technologies help to improve the quality of antibiotic therapy, reduce excess or inappropriate use of antibiotics and deter antibiotic resistance. The real-time bacteria detection and antimicrobial resistance data we collect and aggregate through our network can be used to inform clinical decision-making and the medical community’s response to emerging threats related to infectious disease and antibiotic resistance worldwide.
Location: United States, Missouri, Saint Louis
Employees: 11-50
Total raised: $11M
Founded date: 2004
Investors 1
| Date | Name | Website |
| - | Missouri T... | missourite... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.12.2014 | Series A | $6M | - |
| 27.08.2014 | - | $5M | - |
Mentions in press and media 4
| Date | Title | Description |
| 10.12.2014 | Bacterioscan could cut UTI screening time from several days down to 20 minutes | The company’s device, first developed in Israel, rapidly quantifies bacterial growth in a liquid. It’s already sold a few of its “research only” early models to research institutions, the company says, adding: Today this instrument is at wo... |
| 28.05.2013 | Rapid, benchtop test for UTIs brings in $2M investment for medical device startup | It’s a benchtop instrument for hospital labs that use electro-optic technology to screen urine samples without the use of reagents or the need to be sent to a lab. It reduces physician wait time for results to less than three hours. The gol... |
| - | Bacterioscan could cut UTI screening time from several days down to 20 minutes | The way we diagnose urinary tract infections is still pretty belabored. The most common method is examining a urine sample for errant bacteria or blood cells. Other methods include a urine sample and then trying to grow the bacteria in the ... |
| - | Rapid, benchtop test for UTIs brings in $2M investment for medical device startup | Creating a quicker, cheaper and more accurate way for doctors to test patients for urinary tract infections has netted a St. Louis startup at least $2 million in its latest round of fundraising. Medical device company BacterioScan disclosed... |